Affiliation: GlaxoSmithKline Research and Development
- Lipid rafts mediate the interaction between myelin-associated glycoprotein (MAG) on myelin and MAG-receptors on neuronsMary Vinson
Neurology Centre of Excellence for Drug Discovery, Glaxo SmithKline, New Frontiers Science Park North, Harlow, UK
Mol Cell Neurosci 22:344-52. 2003..Localisation within lipid rafts may provide a molecular environment that facilitates the interaction between MAG and multiple receptors and also between MAG ligands and molecules involved in signal transduction...
- Identification of neuroprotective properties of anti-MAG antibody: a novel approach for the treatment of stroke?Elaine A Irving
Neurology and GI CEDD, GlaxoSmithKline Research and Development Limited, New Frontiers Science Park, Harlow, Essex, UK
J Cereb Blood Flow Metab 25:98-107. 2005..Together, these data highlight the potential for the use of anti-MAG antibodies as therapeutic agents for the treatment of stroke...
- Tissue sparing and functional recovery following experimental traumatic brain injury is provided by treatment with an anti-myelin-associated glycoprotein antibodyHilaire J Thompson
Traumatic Brain Injury Laboratory, Department of Neurosurgery, The University of Pennsylvania, Philadelphia, PA, USA, and Department of Neurosurgery, Uppsala University Hospital, Sweden
Eur J Neurosci 24:3063-72. 2006..05) when compared with their brain-injured controls. These results indicate that MAG may contribute to the pathophysiology of experimental TBI and treatment strategies that target MAG may be suitable for further evaluation...